Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
124 hedge funds and large institutions have $378M invested in Jounce Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 20 closing their positions.
100% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 20
95% more capital invested
Capital invested by funds: $194M → $378M (+$184M)
19% more funds holding
Funds holding: 104 → 124 (+20)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 32
81% less call options, than puts
Call options by funds: $596K | Put options by funds: $3.22M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$35.7M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$25.7M |
| 3 |
O
OrbiMed
New York
|
+$20M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$11.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$29.6M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$6.59M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.53M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.53M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.28M |
JNCE Hedge Fund Activity: Q1 2021 in Review
124 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2021, worth a combined $378M — up 95% from $194M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new JNCE positions and 20 closed out — a net gain of 20 holders — while 32 added to existing stakes and 32 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $35.7M. The largest seller was TRV GP II, cutting an estimated $29.6M.
- 124 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2021, up from 104 in Q4 2020.
- Funds reported $378M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2021, up 95% quarter-over-quarter.
- 40 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2021 and 20 closed out, a net change of +20 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2021 was PFM Health Sciences, an estimated $35.7M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2021 was TRV GP II, an estimated $29.6M sold.
Based on aggregated 13F filings for Q1 2021.